Shares of Vericel Co. (NASDAQ:VCEL – Get Free Report) have been given an average rating of “Buy” by the nine brokerages that are presently covering the stock, MarketBeat Ratings reports. Nine research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have covered the stock in the last year is $55.75.
A number of equities research analysts recently weighed in on the stock. TD Cowen upped their target price on shares of Vericel from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, August 27th. Truist Financial upped their target price on shares of Vericel from $56.00 to $57.00 and gave the stock a “buy” rating in a report on Tuesday, July 16th. Stephens upped their target price on shares of Vericel from $56.00 to $58.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Canaccord Genuity Group assumed coverage on shares of Vericel in a report on Friday, August 9th. They issued a “buy” rating and a $57.00 target price on the stock. Finally, Canaccord Genuity Group began coverage on shares of Vericel in a report on Friday, August 9th. They issued a “buy” rating and a $57.00 target price on the stock.
View Our Latest Report on Vericel
Insider Buying and Selling at Vericel
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. boosted its holdings in Vericel by 104.9% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 4,108 shares of the biotechnology company’s stock worth $188,000 after buying an additional 2,103 shares during the period. Algert Global LLC bought a new position in Vericel in the 2nd quarter worth approximately $213,000. The Manufacturers Life Insurance Company boosted its holdings in Vericel by 5.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,472 shares of the biotechnology company’s stock worth $1,215,000 after buying an additional 1,355 shares during the period. Squarepoint Ops LLC bought a new position in Vericel in the 2nd quarter valued at $513,000. Finally, Public Sector Pension Investment Board boosted its holdings in Vericel by 9.3% in the 2nd quarter. Public Sector Pension Investment Board now owns 106,911 shares of the biotechnology company’s stock valued at $4,905,000 after purchasing an additional 9,084 shares during the period.
Vericel Price Performance
VCEL stock opened at $43.89 on Thursday. The stock has a market capitalization of $2.15 billion, a PE ratio of -4,384.62 and a beta of 1.68. The company’s 50-day moving average is $48.49 and its 200-day moving average is $47.49. Vericel has a 1 year low of $30.18 and a 1 year high of $54.10.
Vericel (NASDAQ:VCEL – Get Free Report) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.10). The company had revenue of $52.70 million for the quarter, compared to analysts’ expectations of $52.59 million. Vericel had a net margin of 0.37% and a return on equity of 0.35%. The business’s revenue was up 14.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.11) EPS. On average, analysts anticipate that Vericel will post 0.1 earnings per share for the current fiscal year.
About Vericel
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
See Also
- Five stocks we like better than Vericel
- The Role Economic Reports Play in a Successful Investment Strategy
- Why Block’s Key Components Make It a Solid Investment Choice
- Dividend Payout Ratio Calculator
- Is Applied Digital’s Stock Set to Surge With NVIDIA’s Backing?
- 5 Top Rated Dividend Stocks to Consider
- 4 Reasons to Consider Adding General Mills to Your Portfolio
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.